查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1628898

骨癌治疗市场，按类型、治疗、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Bone Cancer Treatment Market, By Type, By Treatment, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年骨癌治疗市场规模为13.215亿美元，2024年至2032年复合年增长率为5.50%。

骨癌治疗市场-市场动态

骨癌发生率上升

由于骨癌发生率上升，预计骨癌治疗市场将会扩大。始于骨组织的恶性（癌性）肿瘤称为骨癌。当骨细胞生长失控并分裂，形成肿瘤或肿块时，就会发生这种情况。骨癌治疗的目的是为患者提供许多好处。这种疗法治疗了多种骨恶性肿瘤，包括手术、肢体保留、缓解疼痛、改善生活品质和控制肿瘤。例如，代表美国医生的专业组织美国临床肿瘤学会（ASCO）于 2023 年 2 月报告称，美国将诊断出 3,970 例新原发性骨肉瘤病例（2,160 名男性和 1,810 名女性）到2023 年，15至19 岁族群中将有201 例。

骨癌治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球骨癌治疗市场在预测期内（2024-2032）每年将以 5.50% 左右的复合年增长率成长

根据类型细分，预计原发性骨癌类别将在 2023 年显示最大的市场份额

从治疗细分来看，2023年化疗是领先细分领域

按地区划分，北美是 2023 年的主要收入来源

骨癌治疗市场-細項分析：

全球骨癌治疗市场根据类型、治疗、最终用户和地区进行细分。

根据类型，市场分为原发性骨癌（尤文氏肉瘤、骨肉瘤、软骨肉瘤、其他原发性骨癌）和继发性骨癌。原发性骨癌类别在 2023 年引领市场。这与从身体其他部位扩散的骨癌（通常称为继发性或转移性骨癌）不同。原发性骨癌通常需要专门的治疗方法，包括放射治疗、标靶治疗和保肢手术。此外，与肺癌或乳癌等其他癌症相比，原发性骨癌相对罕见。然而，它的稀缺性并没有削弱它的重要性。原发性骨癌因其发病率极低而成为研究和治疗开发的焦点。

依治疗方法，市场分为标靶治疗和免疫治疗（狄诺塞麦、舒尼替尼、伊马替尼、其他标靶和免疫治疗）、放射治疗、手术和化疗（阿霉素、依托泊苷、顺铂、环磷酰胺、其他化疗）。 2023年，化疗类别成为全球骨癌治疗市场的主导力量。化疗是一种全身性治疗，透过血液传播到身体的各个部位。这项功能使其能够针对原始骨肿瘤以及任何可能的转移或器官扩散中的癌细胞。化疗对于减少肿瘤非常有效，即使是位于骨组织等难以到达的地方的肿瘤也是如此。化疗对于限制骨癌的生长和扩散非常重要，特别是对于处于疾病晚期或明显转移的患者。手术后，化疗常用作辅助治疗。移除手术后可能残留的任何癌细胞可以降低原发性骨癌復发的机会。有时在手术前进行新辅助治疗或化疗。

骨癌治疗市场 - 地理洞察

从地理来看，骨癌治疗市场广泛分布于北美、拉丁美洲、欧洲、亚太地区、中东和非洲地区。这些区域根据开展业务的国家进一步划分。

北美骨癌治疗市场的特点是其发达的医疗基础设施、对研发的高度重视以及高医疗保健支出。该地区强有力的报销政策和监管结构鼓励开发和采用创新的骨癌治疗方案。北美许多生技和製药公司也积极致力于创造骨癌新疗法，例如免疫疗法、标靶药物和个人化医疗策略。由于该地区骨癌发病率上升，尤其是老年人口，该市场也在不断增长。

在整个预测期内，亚太市场预计将以最快的速度成长，为骨癌治疗产业的参与者提供显着的成长前景。亚太地区庞大且不断增长的人口等因素暗示着庞大的患者群体。预计随着医疗保健可近性的改善，骨癌治疗的需求将会增加。在亚太国家，快速的工业化和生活方式的改变导致癌症病例增加，特别是骨癌。这种趋势要求骨癌治疗市场的成长。该地区庞大且多样化的患者群体使其成为临床研究中心。

骨癌治疗市场-竞争格局：

骨癌治疗市场高度分散，主要是因为许多竞争对手在本地和全球范围内运营，例如辉瑞、百特国际公司、Advaxis、安进、Atlanthera、拜耳公司等。对市场整体动态做出贡献的各种公司决定了竞争格局。这种划分是老牌产业参与者、新来者和专业解决方案供应商之间争夺市场份额的结果。利用多种策略来提高公司的知名度凸显了市场参与者的多样性。在全球范围内，所研究行业的企业正在透过积极的扩张计划将自己置于战略地位。例如，Zetagen Therapeutics 的 ZetaMet 技术于 2021 年 12 月被美国食品和药物管理局 (FDA) 设备和放射健康中心 (CDRH) 指定为突破性产品。疾病。这有助于企业加快审查和开发过程。

最新进展：

2024 年 2 月：Telix 宣布有意收购 QSAM Biosciences, Inc. 及其主要实验药物 Samarium-153-DOTMP (153Sm-DOTMP)。一家名为 QSAM 的美国公司生产治疗原发性骨癌和转移性骨癌的放射性药物。透过此次收购，该公司能够扩大客户群并打入未开发的市场。

2023年10月：Zetagen Therapeutics在同行评审期刊《疼痛管理》上发布了ZetaMet的初步临床研究结果。其中包括有关 ZetaMet 对骨转移患者的有效性和安全性的信息。

2023 年 3 月：CADD522 是一种新型药物，由谢菲尔德大学和东安格利亚大学的研究人员创建，用于治疗原发性骨恶性肿瘤患者。在临床前模型中，这种药物使存活率提高了 50%。

目录

第一章：骨癌治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按类型分類的骨癌治疗市场片段
    • 骨癌治疗市场片段（依治疗）
    • 最终用户的骨癌治疗市场片段
    • 按国家/地区分類的骨癌治疗市场片段
    • 按地区分類的骨癌治疗市场片段
  • 竞争洞察

第 3 章：骨癌治疗主要市场趋势

  • 骨癌治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 骨癌治疗市场限制
    • 市场限制影响分析
  • 骨癌治疗市场机会
  • 骨癌治疗市场未来趋势

第 4 章：骨癌治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：骨癌治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：骨癌治疗市场格局

  • 2023 年骨癌治疗市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：骨癌治疗市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 原发性骨癌
      • 尤文氏肉瘤
      • 骨肉瘤
      • 软骨肉瘤
      • 其他原发性骨癌
    • 继发性骨癌

第 8 章：骨癌治疗市场 - 按治疗分类

  • 概述
    • 按处理方式分類的细分市场占有率分析
    • 标靶和免疫治疗
      • 狄诺塞麦
      • 舒尼替尼
      • 伊马替尼
      • 其他标靶和免疫疗法
    • 放射治疗
    • 手术
    • 化疗
      • 阿霉素
      • 依托泊苷
      • 顺铂
      • 环磷酰胺
      • 其他化疗

第 9 章：骨癌治疗市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 门诊手术中心 (ASC)
    • 肿瘤中心和专科诊所
    • 其他的

第 10 章：骨癌治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美骨癌治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按类型）
    • 北美市场规模与预测（以不同处理方式）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲骨癌治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模与预测（按处理方式）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区骨癌治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按类型）
    • 亚太地区市场规模与预测（以不同处理方式）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 韩国
    • 日本
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲骨癌治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按类型）
    • 拉丁美洲市场规模与预测（以不同处理方式）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲骨癌治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按类型）
    • 中东及非洲市场规模及预测（依不同处理方式）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 骨癌治疗产业

  • 竞争仪表板
  • 公司简介
    • Pfizer Inc.
    • Baxter International Inc.
    • Advaxis Inc.
    • Amgen Inc.
    • Atlanthera
    • Bayer AG
    • Debiopharm
    • Spectrum Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company
    • Johnson & Johnson
    • Gradalis Inc.
    • Eli Lilly and Company
    • Hikma Pharmaceutical PLC
    • Novartis AG
    • Recordati Group
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4431

REPORT HIGHLIGHT

Bone Cancer Treatment Market size was valued at USD 1,321.5 Million in 2023, expanding at a CAGR of 5.50% from 2024 to 2032.

When aberrant cells in bone grow out of control, bone cancer occurs. Healthy bone tissue is destroyed in this cancer. Malignant or cancerous bone tumours can occur. Cancer cells can spread throughout the body as a result of malignant bone tumours. Children, teens, and young adults are more likely to experience them than older adults; however, they can appear at any age. Bone cancer can be treated with a variety of methods, including surgery, radiation therapy, chemotherapy, and targeted therapy. The rise in cancer prevalence, the expansion of government efforts, and the spike in product launches and approvals are the main drivers propelling the growth of the bone cancer treatment market. Moreover, a key driver of the market for bone cancer treatments is the rise in bone cancer, particularly osteosarcoma.

Bone Cancer Treatment Market- Market Dynamics

Rising Incidence of Bone Cancer

It is anticipated that the market for bone cancer treatments will expand due to the rising incidence of bone cancer. Malignant (cancerous) tumours that start in bone tissue are referred to as bone cancer. It happens when bone cells grow out of control and divide, creating a tumour or mass. The purpose of bone cancer treatments is to provide patients with a number of benefits. Several bone malignancies were treated with this therapy, which included surgery, limb preservation, pain relief, improved quality of life, and tumour control. For instance, the American Society of Clinical Oncology (ASCO), a professional organization that represents physicians in the United States, reported in February 2023 that 3,970 new cases of primary bone sarcoma (2,160 men and 1,810 women) would be diagnosed in the United States in 2023, out of 201 cases in people aged 15 to 19. Thus, the market for bone cancer treatments is being driven by the rising incidence of bone cancer.

Bone Cancer Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global Bone Cancer Treatment Market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2024-2032)

Based on type segmentation, the primary bone cancer category was predicted to show maximum market share in the year 2023

Based on treatment segmentation, chemotherapy was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Bone Cancer Treatment Market- Segmentation Analysis:

The Global Bone Cancer Treatment Market is segmented on the basis of Type, Treatment, End-user, and Region.

Based on type, the market is categorized into Primary bone cancer (Ewing sarcoma, Osteosarcoma, Chondrosarcoma, Other primary bone cancer) and Secondary bone cancer. The primary bone cancer category led the market in 2023. Primary bone cancer, sometimes referred to as bone sarcoma, is cancer that starts in the bone and does not spread to other organs. This distinguishes it from bone cancer that has spread from other parts of the body, often known as secondary or metastatic bone cancer. Specialized treatment approaches, including radiation therapy, targeted therapies, and limb-sparing procedures, are usually required for primary bone cancer. In addition, compared to other cancers like lung or breast cancer, primary bone cancer is comparatively uncommon. Its scarcity does not, however, lessen its significance. Primary bone cancer is a focus of study and therapeutic development due to its very low incidence.

By treatment, the market is segregated into Targeted and immunotherapy (Denosumab, Sunitinib, Imatinib, Other targeted & immunotherapies), Radiation therapy, Surgery, and Chemotherapy (Doxorubicin, Etoposide, Cisplatin, Cyclophosphamide, Other chemotherapies). In 2023, the chemotherapy category became the leading force in the global market for the treatment of bone cancer. Chemotherapy is a systemic treatment that travels through the bloodstream to all parts of the body. This feature enables it to target cancer cells in the original bone tumour as well as any possible metastases or organ spreads. Chemotherapy works very well in reducing tumours, even ones that are located in difficult-to-reach places like bone tissue. Chemotherapy can be extremely important in limiting the growth and spread of bone cancer, particularly in patients with advanced stages of the illness or significant metastases. Following surgery, chemotherapy is frequently used as an adjuvant treatment. Removing any cancer cells that may have remained after surgery lowers the chance of recurrence in cases of primary bone cancer. Neoadjuvant treatment, or chemotherapy, is sometimes given prior to surgery.

Bone Cancer Treatment Market- Geographical Insights

Geographically, the Bone Cancer Treatment Market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

The market for bone cancer treatments in North America is distinguished by its well-developed healthcare infrastructure, substantial emphasis on research and development, and high healthcare spending. Innovative bone cancer treatment options are encouraged to be developed and adopted by the region's strong reimbursement policies and regulatory structure. Many biotechnology and pharmaceutical companies in North America are also actively working on creating new treatments for bone cancer, such as immunotherapies, targeted medicines, and personalized medicine strategies. The market is also growing as a result of the region's rising incidence of bone cancer, especially among the elderly population.

Throughout the projected period, the Asia-Pacific market is expected to grow at the quickest rate, providing participants in the bone cancer treatment industry with significant growth prospects. A significant patient pool is implied by factors like the Asia-Pacific region's enormous and expanding population. It is anticipated that the need for bone cancer treatment will rise as access to healthcare improves. In Asia-Pacific nations, rapid industrialization and changes in lifestyle are causing a rise in cancer cases, particularly bone cancer. This tendency calls for the market for bone cancer treatments to grow. The region's sizable and varied patient population is making it a centre for clinical studies.

Bone Cancer Treatment Market- Competitive Landscape:

The bone cancer treatment market is highly fragmented, mainly because many competitors are operating both locally and globally, such as Pfizer Inc., Baxter International Inc., Advaxis Inc., Amgen Inc., Atlanthera, Bayer AG, and others. Various companies that all contribute to the overall dynamics of the market defines the competitive landscape. This division results from the competition for market share between established industry players, newcomers, and specialist solution suppliers. The use of a variety of tactics to increase the company's visibility highlights the diversity of market players. Globally, businesses in the industry under study are putting themselves in a strategic position by pursuing aggressive expansion plans. For instance, Zetagen Therapeutics' ZetaMet technology was designated a breakthrough product by the Centers for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) in December 2021. It demonstrates ZetaMet's promise as a cutting-edge therapy for metastatic bone diseases. This aided the business in accelerating the review and development process.

Recent Developments:

February 2024: Telix declared its intention to purchase QSAM Biosciences, Inc. and its primary experimental medication, Samarium-153-DOTMP (153Sm-DOTMP). A U.S.-based business called QSAM creates therapeutic radiopharmaceuticals for bone cancer, both primary and metastatic. The company was able to expand its clientele and break into unexplored markets thanks to this acquisition.

October 2023: Zetagen Therapeutics released ZetaMet's preliminary clinical study results in the peer-reviewed journal Pain Management. This includes information on ZetaMet's effectiveness and safety in patients with bone metastases.

March 2023: CADD522, a novel medication, was created by researchers at the Universities of Sheffield and East Anglia to treat patients with primary bone malignancies. In preclinical models, this medication increased survival rates by 50%.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BONE CANCER TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • Baxter International Inc.
  • Advaxis Inc.
  • Amgen Inc.
  • Atlanthera
  • Bayer AG
  • Debiopharm
  • Spectrum Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company
  • Johnson & Johnson
  • Gradalis Inc.
  • Eli Lilly and Company
  • Hikma Pharmaceutical PLC
  • Novartis AG
  • Recordati Group
  • Others

GLOBAL BONE CANCER TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Primary bone cancer
  • Ewing sarcoma
  • Osteosarcoma
  • Chondrosarcoma
  • Other primary bone cancer
  • Secondary bone cancer

GLOBAL BONE CANCER TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Targeted and immunotherapy
  • Denosumab
  • Sunitinib
  • Imatinib
  • Other targeted & immunotherapies
  • Radiation therapy
  • Surgery
  • Chemotherapy
  • Doxorubicin
  • Etoposide
  • Cisplatin
  • Cyclophosphamide
  • Other chemotherapies

GLOBAL BONE CANCER TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Ambulatory surgical centers (ASCs)
  • Oncology centers & specialty clinics
  • Others

GLOBAL BONE CANCER TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bone Cancer Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bone Cancer Treatment Market Snippet by Type
    • 2.1.2. Bone Cancer Treatment Market Snippet by Treatment
    • 2.1.3. Bone Cancer Treatment Market Snippet by End-user
    • 2.1.4. Bone Cancer Treatment Market Snippet by Country
    • 2.1.5. Bone Cancer Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Bone Cancer Treatment Key Market Trends

  • 3.1. Bone Cancer Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bone Cancer Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bone Cancer Treatment Market Opportunities
  • 3.4. Bone Cancer Treatment Market Future Trends

4. Bone Cancer Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bone Cancer Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bone Cancer Treatment Market Landscape

  • 6.1. Bone Cancer Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bone Cancer Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Primary bone cancer
      • 7.1.2.1. Ewing sarcoma
      • 7.1.2.2. Osteosarcoma
      • 7.1.2.3. Chondrosarcoma
      • 7.1.2.4. Other primary bone cancer
    • 7.1.3. Secondary bone cancer

8. Bone Cancer Treatment Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 8.1.2. Targeted and immunotherapy
      • 8.1.2.1. Denosumab
      • 8.1.2.2. Sunitinib
      • 8.1.2.3. Imatinib
      • 8.1.2.4. Other targeted & immunotherapies
    • 8.1.3. Radiation therapy
    • 8.1.4. Surgery
    • 8.1.5. Chemotherapy
      • 8.1.5.1. Doxorubicin
      • 8.1.5.2. Etoposide
      • 8.1.5.3. Cisplatin
      • 8.1.5.4. Cyclophosphamide
      • 8.1.5.5. Other chemotherapies

9. Bone Cancer Treatment Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Ambulatory surgical centers (ASCs)
    • 9.1.4. Oncology centers & specialty clinics
    • 9.1.5. Others

10. Bone Cancer Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bone Cancer Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bone Cancer Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bone Cancer Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Bone Cancer Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Bone Cancer Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bone Cancer Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
    • 11.2.2. Baxter International Inc.
    • 11.2.3. Advaxis Inc.
    • 11.2.4. Amgen Inc.
    • 11.2.5. Atlanthera
    • 11.2.6. Bayer AG
    • 11.2.7. Debiopharm
    • 11.2.8. Spectrum Pharmaceuticals Inc.
    • 11.2.9. Takeda Pharmaceutical Company
    • 11.2.10. Johnson & Johnson
    • 11.2.11. Gradalis Inc.
    • 11.2.12. Eli Lilly and Company
    • 11.2.13. Hikma Pharmaceutical PLC
    • 11.2.14. Novartis AG
    • 11.2.15. Recordati Group
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us